Dogwood Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Accrued Expenses

12 Months Ended

Dec. 31, 2023

5. Accrued Expenses

Accrued expenses consist of the following:


	December 31,		December 31,
	2023		2022
Accrued interest on preferred members’ interests	$	188,085	$	188,085
Accrued director fees		31,000		31,000
Accrued professional fees		27,550		11,600
Accrued compensation		—		159,704
Accrued clinical research costs		—		78,349
Other miscellaneous accrued expenses		—		1,360
	$	246,635	$	470,098